Novavax, Inc. (NASDAQ:NVAX) Receives $9.80 Consensus PT from Analysts

Novavax, Inc. (NASDAQ:NVAX) has been assigned a consensus recommendation of “Reduce” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $9.80.

A number of research firms recently commented on NVAX. Weiss Ratings reissued a “sell (d+)” rating on shares of Novavax in a report on Wednesday, October 8th. HC Wainwright started coverage on Novavax in a research report on Thursday, August 28th. They set a “buy” rating and a $10.00 target price on the stock. Finally, Bank of America reaffirmed an “underperform” rating and issued a $7.00 price objective (down previously from $9.00) on shares of Novavax in a research report on Wednesday, August 20th.

Institutional Investors Weigh In On Novavax

A number of hedge funds have recently made changes to their positions in NVAX. GAMMA Investing LLC lifted its stake in shares of Novavax by 2,272.5% during the 1st quarter. GAMMA Investing LLC now owns 11,839 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 11,340 shares during the last quarter. Oppenheimer & Co. Inc. raised its stake in Novavax by 16.4% in the first quarter. Oppenheimer & Co. Inc. now owns 50,738 shares of the biopharmaceutical company’s stock valued at $325,000 after buying an additional 7,165 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Novavax by 4.1% in the first quarter. Bank of New York Mellon Corp now owns 454,432 shares of the biopharmaceutical company’s stock valued at $2,913,000 after buying an additional 17,981 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in Novavax in the first quarter valued at about $290,000. Finally, Hussman Strategic Advisors Inc. raised its stake in Novavax by 100.0% in the first quarter. Hussman Strategic Advisors Inc. now owns 168,000 shares of the biopharmaceutical company’s stock valued at $1,077,000 after buying an additional 84,000 shares during the last quarter. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Novavax Stock Down 1.5%

Shares of NASDAQ NVAX opened at $8.46 on Monday. The stock has a market capitalization of $1.37 billion, a P/E ratio of 3.71, a PEG ratio of 0.11 and a beta of 2.74. Novavax has a one year low of $5.01 and a one year high of $11.55. The company has a debt-to-equity ratio of 5.93, a current ratio of 2.36 and a quick ratio of 2.34. The firm’s 50 day simple moving average is $8.44 and its two-hundred day simple moving average is $7.40.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.69. Novavax had a negative return on equity of 142.33% and a net margin of 39.20%.The company had revenue of $239.24 million during the quarter, compared to analyst estimates of $149.19 million. During the same quarter last year, the firm posted $0.99 earnings per share. The firm’s revenue was down 42.4% on a year-over-year basis. As a group, analysts expect that Novavax will post -1.46 EPS for the current fiscal year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.